Press Releases

 
Press Releases
  Date Title and Summary View
Oct 10, 2017
SAN DIEGO, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women's reproductive health, today announced that Sabrina Martucci Johnson, President and Chief Executive Officer, will present at the 2017 BIO Investor Forum on ...
Sep 7, 2017
SAN DIEGO, Sept. 07, 2017 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a healthcare company committed to the development and commercialization of innovative products in women's reproductive health, today announced that Sabrina Martucci Johnson, Chief Executive Officer and Founder, will present at the 19th Annual Rodman & Renshaw ...
Aug 30, 2017
SAN DIEGO, Aug. 30, 2017 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a healthcare company committed to the development and commercialization of innovative products in women's reproductive health, today announced that Sabrina Martucci Johnson, Chief Executive Officer and Founder, will present at the Liolios 6th Annual Gateway Con...
Aug 15, 2017
SAN DIEGO, Aug. 15, 2017 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE) and the CEO, Sabrina Martucci Johnson, were featured in a San Diego Business Journal article published on August 14, 2017 titled Women Founders: How to get Men to Relate.  The article discussed the funding landscape for products focused on female consumers.  Two...
Aug 3, 2017
SAN DIEGO, Aug. 03, 2017 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE) discussed with Wall Street Analyzer key goals over the next twenty-four months, including the Ovaprene® clinical development program, the memorandum of understanding with CONRAD to enter into an agreement in connection with a postcoital test (PCT) clinical ...
Jul 24, 2017
SAN DIEGO, July 24, 2017 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE) announced today that it has entered into a memorandum of understanding with CONRAD to enter into an agreement in connection with a postcoital test (PCT) clinical trial of Ovaprene®, wherein CONRAD will provide certain clinical and regulatory services relate...
Jul 20, 2017
Company focused on the development and commercialization of women's reproductive health productsDaré to Host Conference Call on Monday, July 24, 2017, at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time to Discuss Business Opportunity SAN DIEGO, July 20, 2017 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE) (formerly known ...
Jul 19, 2017
WALTHAM, Mass. & SAN DIEGO--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU) and Daré Bioscience Operations, Inc. (formerly Daré Bioscience, Inc.) today announced the closing of the transactions contemplated by the stock purchase agreement entered into by the companies on March 19, 2017. As a result...
Jul 5, 2017
WALTHAM, Mass. & SAN DIEGO--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU) and Daré Bioscience, Inc. today announced that Daré Founder and CEO Sabrina Martucci Johnson mailed the following letter to Cerulean stockholders of record at the close of business on June 9, 2017 outlining the Daré va...
Jun 27, 2017
WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU) today urged stockholders of record at the close of business on June 9, 2017 to vote FOR all of the proposals at the upcoming special meeting of stockholders to be held on July 19, 2017. Each of the proposals is an import...
Page:
1
NextLast
= add release to Briefcase
Shareholder tools